Targeting lysine acetyltransferase 6A/B in cancer: a conceptual and translational review of epigenetic regulation, immune microenvironment remodeling, and the dual-compartment hypothesis
- 1Breast Cancer Center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology
Abstract
While lysine acetyltransferase 6A (KAT6A; MOZ/MYST3) and 6B (KAT6B; MORF/MYST4) function as context-dependent oncogenic drivers—with KAT6B also displaying tissue-specific tumor-suppressive roles—their pharmacological targeting holds promise as a therapeutic avenue. This conceptual and translational review synthesizes evidence from genetic depletion models, pharmacological catalytic inhibitors, and emerging proteolysis-targeting chimera (PROTAC) degraders, introducing the “Dual-Compartment Hypothesis” as a conceptual interpretive framework to organize current evidence and generate testable hypotheses regarding their putative impacts on the tumor immune microenvironment (TIME). Under this framework, KAT6A/B blockade within the primary tumor compartment is proposed to indirectly foster regional antitumor immunity via preclinically implicated pathways, including tumor cell ferroptosis, cyclic GMP-AMP synthase–stimulator of interferon genes (cGAS-STING) activation, and interleukin-6 (IL-6) suppression, alongside putative downstream influences on immune checkpoints. In contrast, systemic drug exposure in the secondary compartment may directly alter hematopoiesis and lymphocyte development, creating a tension between local immune activation and systemic constraints. Importantly, immune cells within the tumor microenvironment may also be directly suppressed by KAT6A/B inhibition—an alternative outcome that remains to be systematically investigated. Resolving these divergent outcomes necessitates distinguishing genetic knockout/knockdown (KO/KD) from pharmacological inhibition or degradation—a distinction that is critical because much of the mechanistic evidence derives from genetic models, while accounting for KAT6A versus KAT6B isoform selectivity. Finally, we outline testable translational frameworks, such as intermittent dosing schedules and rational immunotherapeutic combinations, to direct subsequent experimental and clinical validation, while acknowledging that current early-phase clinical observations (objective response rate [ORR]/clinical benefit rate [CBR]) reflect composite therapeutic responses and require further paired biomarker validation to definitively isolate immune-mediated effects.
Related
- KMT2A modulates the epigenetic landscape of rDNA by facilitating the recruitment of histone lysine acetyltransferase PCAF to the rDNA locus.
- RNA therapeutics in rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis: a compartment-aware translational framework
- Nanopore Sequencing for Epigenetic Decoding: Applications, Analytical Constraints, and Translational Prospects
- Divergent roles of H3K18 lactylation in human diseases: metabolic-epigenetic circuits and translational challenges
- Decoding pyroptosis at single-cell resolution: heterogeneity, microenvironment remodeling and potential translational insights
BibTeX
@article{ma2026targeting,
title = {{Targeting lysine acetyltransferase 6A/B in cancer: a conceptual and translational review of epigenetic regulation, immune microenvironment remodeling, and the dual-compartment hypothesis}},
author = {Cong Ma and Jingru Wang and Guanhua Qiao and Xinhong Wu and Hongmei Zheng},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1961903},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1961903/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Targeting lysine acetyltransferase 6A/B in cancer: a conceptual and translational review of epigenetic regulation, immune microenvironment remodeling, and the dual-compartment hypothesis
AU - Cong Ma
AU - Jingru Wang
AU - Guanhua Qiao
AU - Xinhong Wu
AU - Hongmei Zheng
PY - 2026
DA - 2026/10/06
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1961903
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1961903/full
AB - While lysine acetyltransferase 6A (KAT6A; MOZ/MYST3) and 6B (KAT6B; MORF/MYST4) function as context-dependent oncogenic drivers—with KAT6B also displaying tissue-specific tumor-suppressive roles—their pharmacological targeting holds promise as a therapeutic avenue. This conceptual and translational review synthesizes evidence from genetic depletion models, pharmacological catalytic inhibitors, and emerging proteolysis-targeting chimera (PROTAC) degraders, introducing the “Dual-Compartment Hypothesis” as a conceptual interpretive framework to organize current evidence and generate testable hypotheses regarding their putative impacts on the tumor immune microenvironment (TIME). Under this framework, KAT6A/B blockade within the primary tumor compartment is proposed to indirectly foster regional antitumor immunity via preclinically implicated pathways, including tumor cell ferroptosis, cyclic GMP-AMP synthase–stimulator of interferon genes (cGAS-STING) activation, and interleukin-6 (IL-6) suppression, alongside putative downstream influences on immune checkpoints. In contrast, systemic drug exposure in the secondary compartment may directly alter hematopoiesis and lymphocyte development, creating a tension between local immune activation and systemic constraints. Importantly, immune cells within the tumor microenvironment may also be directly suppressed by KAT6A/B inhibition—an alternative outcome that remains to be systematically investigated. Resolving these divergent outcomes necessitates distinguishing genetic knockout/knockdown (KO/KD) from pharmacological inhibition or degradation—a distinction that is critical because much of the mechanistic evidence derives from genetic models, while accounting for KAT6A versus KAT6B isoform selectivity. Finally, we outline testable translational frameworks, such as intermittent dosing schedules and rational immunotherapeutic combinations, to direct subsequent experimental and clinical validation, while acknowledging that current early-phase clinical observations (objective response rate [ORR]/clinical benefit rate [CBR]) reflect composite therapeutic responses and require further paired biomarker validation to definitively isolate immune-mediated effects.
SN - 1664-3224
ER -